NCT06771115

Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 Alone or in Combination With Semaglutide in Participants With Obesity

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 176 (actual)
• Sponsor: Zomagen Biosciences Ltd. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide. This study consists of a 30-day Screening Period (to see if a participant qualifies for a study), a 12-week double-blind treatment period (a participant receives VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide), and a 30-day Follow-Up Period. The maximum duration of treatment will be approximately 12 weeks.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	VTX3232 Dose A	VTX3232 Dose A
DRUG	Placebo	Placebo
DRUG	VTX3232 Dose A in combination with semaglutide	VTX3232 Dose A in combination with semaglutide
DRUG	Placebo in combination with semaglutide	Placebo in combination with semaglutide

Timeline

• Start date: 2025-01-07
• Primary completion: 2025-09-10
• Completion: 2025-09-10
• First posted: 2025-01-13
• Last updated: 2025-11-10

Locations

14 sites across 1 country: United States

Regulatory

• FDA-regulated drug study